FCA
CHRS icon

FinTrust Capital Advisors’s Coherus Oncology CHRS Stock Holding History

FinTrust Capital Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,000
Closed -$3K – 1195
2021
Q3 		$3K Buy
+1,000
New +$14.7K ﹤0.01% 1062

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

FinTrust Capital Advisors's CHRS Position: Q1 2022 in Review

FinTrust Capital Advisors sold out of Coherus Oncology (CHRS) in Q1 2022, closing a stake of 27,500 shares — an estimated $439K sold.

FinTrust Capital Advisors first reported a position in CHRS in Q4 2019 and held it in 7 quarters. The position peaked at $442K in Q3 2021. 183 funds tracked by Wall St. Rank hold CHRS as of Q1 2022.

  • FinTrust Capital Advisors reported no remaining Coherus Oncology position as of Q1 2022 after selling out during the quarter.
  • FinTrust Capital Advisors sold 27,500 Coherus Oncology shares in Q1 2022, an estimated $439K.
  • FinTrust Capital Advisors first reported a position in Coherus Oncology in Q4 2019 and held it in 7 quarters.
  • FinTrust Capital Advisors's Coherus Oncology position peaked at $442K in Q3 2021.
  • 183 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2022.

Based on FinTrust Capital Advisors's 13F filing for Q1 2022, filed 3 May 2022.